Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Aug 19;2(4):177-180.
doi: 10.1002/cld.220. eCollection 2013 Aug.

Hepatitis C virus: Management of recurrent disease

Elizabeth C Verna  1
Affiliations
Review

Hepatitis C virus: Management of recurrent disease

Elizabeth C Verna. Clin Liver Dis (Hoboken). .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
After the initiation of HCV treatment, survival is higher for HCV‐positive LT recipients who achieve SVR (with 1‐, 3‐, and 5‐year survival rates of 96%, 94%, and 94%, respectively) versus nonresponders (97%, 73%, and 68%, respectively; P = 0.012, log‐rank test). Reprinted with permission from Journal of Hepatology.7 Copyright 2012, Elsevier.
Figure 2
Figure 2
(A) Dose‐normalized mean (standard deviation) blood concentration–time profiles for cyclosporine after the administration of cyclosporine alone or with telaprevir (a log‐linear scale). (B) Dose‐normalized mean (standard deviation) blood concentration–time profiles for tacrolimus after the administration of tacrolimus alone or with telaprevir (a log‐linear scale). Reprinted with permission from Hepatology.11 Copyright 2011, American Association for the Study of Liver Diseases.
Figure 3
Figure 3
The cumulative hazard of graft failure due to recurrent disease is higher in patients who receive tacrolimus as their primary immunosuppression versus patients who receive cyclosporine (hazard ratio = 1.4, P = 0.007) in the United Network for Organ Sharing database. Reprinted with permission from American Journal of Transplantation.24 Copyright 2011, American Society of Transplantation and American Society of Transplant Surgeons.
See this image and copyright information in PMC

References

    1. Shergill AK, Khalili M, Straley S, Bollinger K, Roberts JP, Ascher NA, et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C‐infected patients undergoing liver transplantation. Am J Transplant 2005; 5: 118‐124. - PubMed
    1. Bzowej N, Nelson DR, Terrault NA, Everson GT, Teng LL, Prabhakar A, et al. PHOENIX: a randomized controlled trial of peginterferon alfa‐2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl 2011; 17: 528‐538. - PMC - PubMed
    1. Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9: S1‐S9. - PubMed
    1. Carrion JA, Fernandez‐Varo G, Bruguera M, Garcia‐Pagan JC, Garcia‐Valdecasas JC, Perez‐Del‐Pulgar S, et al. Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation. Gastroenterology 2010; 138: 147‐158. - PubMed
    1. Vergniol J, Foucher J, Terrebonne E, Bernard PH, le Bail B, Merrouche W, et al. Noninvasive tests for fibrosis and liver stiffness predict 5‐year outcomes of patients with chronic hepatitis C. Gastroenterology 2011; 140: 1970‐1979. - PubMed